Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 1Breast 1

Conditions

Squamous Cell Carcinoma of Head and Neck 2Neoplasm Metastasis 2Head and Neck Neoplasms 2Urinary Bladder Neoplasms 1Stomach Neoplasms 1Neoplasms 1Lymphoma, Non-Hodgkin 1Leukemia, Myeloid, Acute 1HER2-expressing Cancers 1Carcinoma, Transitional Cell 1Breast Neoplasms 1

Interventions

pembrolizumab 98Gemcitabine 70Paclitaxel 59Docetaxel 52Carboplatin 49Cisplatin 40Nivolumab 39Capecitabine 35Pemetrexed 33Fluorouracil 32Bevacizumab 32Cetuximab 31130-nm albumin-bound paclitaxel 28Trastuzumab 26Irinotecan 24Albumin-Bound Paclitaxel 24Fulvestrant 22Leucovorin 20Oxaliplatin 18Panitumumab 17abemaciclib 16Ipilimumab 16Cyclophosphamide 15cemiplimab 14atezolizumab 14Letrozole 14palbociclib 12Lapatinib 12Drug Therapy 12Doxorubicin 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Neoplasm Metastasis × ALX148 × Clear all
NCT07007559 2026-06-05

ASPEN-09-03

ALX Oncology Inc.

Phase 2 Recruiting
120 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT03013218 2025-08-01

A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)

ALX Oncology Inc.

Phase 1 Completed
174 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡